Argentine consensus of congenital toxoplasmosis;Consenso Argentino de toxoplasmosis congenita

Medicina

Volumn 68, Issue 1, 2008, Pages 75-87

  Durlach, Ricardo ^a   Kaufer, Federico ^a   Carral, Liliana ^a   Freuler, Cristina ^a   Ceriotto, Mariana ^b   Rodriguez, Marcelo ^c   Freilij, Hector ^d   Altcheh, Jaime ^d   Vazquez, Liliana ^e   Corazza, Rosana ^f   Fontana, Maria Dalla ^g   Arienti, Hector ^h   Sturba, Edgardo ^e   Gonzalez Ayala, Silvia ⁱ   Cecchini, Emilio ^j   Salomon, Cristina ^k   Nadal, Monica ^l   Gutierrez, Nestor ^m   Guarnera, Eduardo ⁿ  

^a Epidemiología del Hospital   (Argentina)

^b Hospital Cecilla Grierson   (Argentina)

^c Administracion Nacional de Laboratorios E Institutos de Salud Dr Carlos G Malbran   (Argentina)

^d HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^e Centro de Estudios Infectológicos   (Argentina)

^f Hospital Eva Peron   (Argentina)

^g Red de Laboratorios de la Provincia Santa Fe   (Argentina)

^h Red Provincial de Toxoplasmosis ^*  (Argentina)

ⁱ Hospital de Ninos Sor Maria Ludovica   (Argentina)

^j FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^k UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^l Laboratorio Central   (Argentina)

^m UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

ⁿ INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

more..

Author keywords

Argentine consensus; Congenital toxoplasmosis; Diagnosis; Postnatal; Therapy; Toxoplasmosis

Indexed keywords

CLINDAMYCIN; FOLIC ACID; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE; PROTOZOON ANTIBODY;

ARGENTINA; ARTICLE; BLOOD SAMPLING; CONGENITAL TOXOPLASMOSIS; CONSENSUS; DISEASE TRANSMISSION; FOLLOW UP; HUMAN; INCIDENCE; PERINATAL PERIOD; PREGNANCY; PRENATAL DIAGNOSIS; RISK REDUCTION; SCREENING; SENSITIVITY AND SPECIFICITY; SEROLOGY; TOXOPLASMA GONDII; BLOOD; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; MASS SCREENING; NEWBORN; NEWBORN SCREENING; PREGNANCY COMPLICATION; RISK FACTOR;

ANTIBODIES, PROTOZOAN; ARGENTINA; FEMALE; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MASS SCREENING; NEONATAL SCREENING; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; PRENATAL DIAGNOSIS; RISK FACTORS; TOXOPLASMOSIS, CONGENITAL;

EID: 42049111399     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Dubey JP. Sources of Toxoplasma gondii infection in pregnancy. Br Med J 2000; 321: 127-8.
2. Acha PN, Szyfres B. Toxoplasmosis. En: Acha PN, Szyfres B (eds). Zoonosis y enfermedades transmisibles comunes al hombre y a los animales. 2da ed. Washington: Organización Panamericana de la Salud, 1986, p 646-58.
3. Hirt J. Fuente de infección y mecanismo de transmission. En: Hirt J.(ed) Toxoplasmosis. 1era ed. Buenos Aires: El Ateneo, 1974, p 22-32.
4. Hirt J, Durlach R. Toxoplasmosis prenatal. Editorial. Infect Microbiol Clin 1995; 2: 7-8.
5. Dunn D, Wallon M, Peyron F, Petersen F, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling. Lancet 1999; 353: 1829-33.
6. Gras L, Wallon M, Pollak A, et al. Association between prenatal treatment and clinical manifestation of congenital toxoplasmosis in infancy: a cohort study in 13 european centres. Acta Paediatrica 2005; 94: 1721-31.
7. Foulon W, Villena I, Stray-Pedersen B, et al. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at one year of age. Am J Obstet Gynecol 1999; 180: 410-5.
8. Gilbert R, Dunn D, Wallon M, et al. Ecological comparison of the risks of mother-to-child transmission and clinical manifestations of congenital toxoplasmosis according to prenatal treatment protocol. Epidemiol Infect 2001; 127: 113-20.
9. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracranial and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiology 2001; 30: 1309-13.
10. The SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patient data. Lancet 2007; 369: 115-22.
11. Ambroise-Thomas P. Congenital toxoplasmosis: les différentes strategies préventives. Arch Pediat 2003; 10: 12-4.
12. Montoya JG, Kovacs JA, Remington JS. Toxoplasma gondii. In: Mandell GL, Bennett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005, p 3170-98.
13. Desmonts G, Couvreur J. Congenital toxoplasmosis: a prospective study of 378 pregnancies. N Engl J Med 1974; 290: 1110-6.
14. Aspöck H. Prevention of congenital toxoplasmosis in Austria: experience of 25 years. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 1277-92.
15. Gilbert R. Epidemiology of infection in pregnant women. In: Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. P Ambroise-Thomas, E Petersen (eds). Chateau-Gontier, France: Springer, 2000, p 237-49.
16. Durlach R, Kaufer F, Carral L, et al. Prevalencia de anticuerpos anti- Toxoplasma gondii en mujeres embarazadas en la República Argentina. XI Congreso Panamericano de Infectología. Córdoba, 2003, p74.
17. Kaufer F, Carral L, Durlach R, Hirt J. Estudio de prevalencia e incidencia de toxoplasmosis en embarazadas. IV Congreso Argentino de Zoonosis. Buenos Aires, 2004.
18. Durlach R, Kaufer F, Carral L, Hirt J, Schmee E. Seroprevalencia 2002. XI Congreso Panamericano de Infectología. Córdoba, 2003, p 38.
19. Camargo Neto E, Anele E, Rubim R, et al. High prevalence of congenital toxoplasmosis in Brazil estimated in a 3-years prospective neonatal screening study. Int J Epidemiol 2000; 29: 941-7.
20. Roizen N, Swisher CN, Stein MA, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995, 1: 11-20.
21. Desmonts G, Couvreur J. Toxoplasmosis in pregnancy and its transmission to the fetus. Bull N Y Acad Med 1974; 50: 146-59.
22. Wallon M, Cozon G, Ecochard R, Lewin P, Peyron F. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur J Pediatr 2001; 160: 534-40.
23. Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: Outcome of pregnancy and infant follow-up after in utero treatment. J Pediatrics 1989; 115: 765-9.
24. Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J Antimicrob Chemother 1988; 22: 193-200.
25. Couvreur J. Le problème de la toxoplasmose congénitale. L'évolution sur quatre decénnies. Presse Med 1999; 28: 753-7.
26. Wallon M, Kodjikian L, Binquet C, et al. Long-Term Ocular Prognosis in 327 Children with Congenital Toxoplasmosis. Pediatrics 2004; 113: 1567-72.
27. Daffos F, Forestier F, Capella-Pavlovsky M, et al. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. N Engl J Med 1988; 318: 271-5.
28. Foulon W. Congenital toxoplasmosis. Is screening desirable?. Scand J Infect Dis 1992; S84: 11-17.
29. McAuley J, Boyer Km, Patel D, et al. Early and longitudinal evaluation of treated infants and children and untreated historical patients with congenital toxoplasmosis: The Chicago Collaborative Treatment Trial. Clin Infect Dis 1994; 18: 38-72.
30. Couvreur J, Thulliez P, Daffos F, et al. In utero treatment of toxoplasmic fetophaty with the combination pyrime-tamine-sulfadiazine. Fetal Diagn Ther 1993; 8: 45-50.
31. Desmonts G, Couvreur J. Toxoplasmose congénitale. Étude prospective de l'issue de la grossesse chez 542 femmes atteintes de toxoplasmose acquise en cours de gestation. Annales de Pédiatrie 1984; 31: 805-9.
32. Alford CA, Stagno S, Reynolds DW. Congenital toxoplasmosis: clinical, laboratory and therapeutical considerations, with special reference to subclinical disease. Bull NY Acad Med 1974; 50: 160-81.
33. Hirt J. Toxoplasmosis congénita. En: Cacchionne R, Durlach R, Larghi OP (eds). Temas de Zoonosis II. Buenos Aires: Asociación Argentina de Zoonosis, 2004, p 297-304.
34. Petersen E, Eaton RB. Neonatal screening for congenital infection with Toxoplasma gondii. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 305-12.
35. Romand S, Thuliez P. Laboratory diagnosis of fetal toxoplasmosis. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p131-9.
36. Durlach R, Kaufer F, Carral L, Hirt J. Toxoplasmic lymphadenitis-clinical and serologic profile. Clin Microbiol Infect 2003; 9: 625-31.
37. Holland G. Ocular toxoplasmosis: A global reassessment. Part I: Epidemiology and course of disease. Am J Ophthalmol 2003; 973-88.
38. Remington JS, McLeod R, Thulliez F, Desmonts G. Toxoplasmosis. In: Remington JS, Klein JO, Wilson CB, Baker CJ (eds). Infectious Diseases of Fetus and Newborn Infant. 6th ed. Philadelphia: Elsevier-Saunders Company, 2006, p 947-1091.
39. Hayde M, Pollak A. Clinical picture. Neonatal signs and symptoms. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 153-63.
40. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002; 8: 634-40.
41. Frenkel JK. La inmunidad de la toxoplasmosis. Bol Of Panam 1986; 100: 283-98.
42. Piergili Fioretti D. Laboratory diagnosis of Toxoplasma gondii infection: correlation between the conventional and in progress methods. Parasitolog 2004; 1-2: 177-81.
43. Pinon JM, Dumon H, Chemla C, et al. Strategy for diagnosis of congenital toxoplasmosis: Evaluation of methods comparing mothers and newborns and standard methods for postnatal detection of immunoglobulin G, M and A antibodies. J Clin Microbiol 2001; 39: 2267-71.
44. Robert-Gangneux F, Gavinet MF, Ancelle T, Raymond J, Tourte-Schaeffer C, Dupuy-Camet J. Value of prenatal diagnosis and early postnatal diagnosis of congenital toxoplasmosis: Retrospective Study of 110 Cases. J Clin Microbiol 1999; 37: 2893-8.
45. Walton BC, Benchoff BM, Brooks WH. Comparison of the indirect fluorescent antibody test and methylene blue dye test for detection of antibodies to Toxoplasma gondii. Am J Trop Med Hyg 1966; 15: 149-52.
46. Desmonts G, Remington JS. Direct agglutination test for diagnosis of Toxoplasma infection: method for increasing sensitivity and specificity. J Clin Microbiol 1980; 11: 562-8.
47. Press C, Montoya JG, Remington JS. Use of a single serum sample for diagnosis of acute toxoplasmosis in pregnant women and other adults. J Clin Microbiol 2005; 43: 3481-3.
48. Welch PC, Masur H, Jones TC, Remington JS. Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis. 1980; 142: 256-64.
49. Balfour AH, Bridges JB, Harford JP. An evaluation of the ToxHA test for the detection of antibodies to Toxoplasma gondii in human serum. J Clin Pathol 1980; 33: 644-7.
50. Thulliez P, Romand S. Prenatal screening and prevention of congenital toxoplasmosis in France. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 293-8.
51. Saathoff M, Seitz HM. Untersuchung von Neugeborenenund Fetalseren zur Erfassung von konnatalen Toxoplasma-Infektionen. Z Geburtsh Perinatol 1991; 195: 262-6.
52. Desmonts G, Naot Y, Remington JS. Immunoglobulin M-immunosorbent agglutination assay for diagnosis of infectious diseases: diagnosis of acute congenital and acquired Toxoplasma infections. J Clin Microbiol 1981; 14: 486-91.
53. Gross U, Montag-Lessing T. Toxoplasmose in der Schwangerschaft: "IgM did more harm than good". Hyg Mikrobiol 1998; 2: 25-7.
54. Liesenfeld O, Press C, Montoya JG, et al. False-positive results in inmunoglobulin M (IgM) Toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM Test. J Clin Microbiol 1997; 35: 174-8.
55. Grover CM, Thulliez P, Remington JS, Boothroyd JD. Rapid prenatal diagnosis of congenital Toxoplasma infection by using polymerase chain reaction and amniotic fluid. J Clin Microbiol 1990; 28: 2297-301.
56. Hofgartner WT, Swanzy SR, Bacina RM, et al. Detection of immunoglobulin G (IgG) and IgM antibodies to Toxoplasma gondii: Evaluation of four commercial immunoassay systems. J Clin Microbiol 1997; 35: 3313-5.
57. Saathoff M, Seitz HM. Nachweis von toxoplasmas-pezifischen IgA und IgM-Antikörpern in Serumproben von Erwachsenen mit erworbener Toxoplasma Infektion. Z Geburtsh Perinat 1992; 196: 221-3.
58. Foudrinier F, Marx-Chemla C, Aubert D, Bonhomme A, Pinon JM. Value of specific immunoglobulin A detection by two immunocapture assays in the diagnosis of toxoplasmosis. Eur J Clin Microbiol Infect Dis 1995; 14: 585-90.
59. van Loon AM, van der Veen J. Enzyme-linked immunosorbent assay for quantitation of toxoplasma antibodies in human sera. J Clin Pathol 1980; 33: 635-9.
60. FDA Public Health Advisory: Limitations of Toxoplasma IgM commercial test kits 1997; 25: 1-3.
61. De Meuter F, De Decker H. Indirect fluorescent antibody test in toxoplasmosis. Advantage of the use of fluorescent anti-IgG conjugate. Zentralbl Bakteriol 1975; 233: 421-30.
62. Naot Y, Barnett EV, Remington JS. Method for avoiding false positive results occurring in immunoglobulin M enzyme-linked immunosorbent assays due to presence of both rheumatoid factor and antinuclear antibodies. J Clin Microbiol 1983; 17: 939-41.
63. Durlach R, Carral L, Kaufer F, Hirt J. Use of IgM titers to predict acute Toxoplasmic infection after lymphadenitis onset. 35th. Annual Meeting of the Infectious Diseases Society of America 1997. San Francisco, E.E.U.U. Clin Infect Dis 1997; p 60 (Abstract).
64. Reiter-Owona I, Petersen E, Joynson D, et al. The past and present role of the Sabin-Feldman dye test in the serodiagnosis of toxoplasmosis. Bull World Health Organ 1999; 77: 929-35.
65. Sabin AB, Feldman HA. Dyes as microchemical indicators of a new immunity phenomenon affecting a protozoan parasite (Toxoplasma) Science 1949; 108: 660-3.
66. Empfehlungen für die Durchführung der Toxoplasma-Seroreaktionen mittels Mikromethode. Bundesgesundheitsblatt 1977; 20: 108-12.
67. Stepick-Biek P, Thulliez P, Araujo FG, Remington JS. IgA antibodies for diagnosis of acute congenital and acquired toxoplasmosis. J Infect Dis 1990; 162: 270-3.
68. Wong SY, Hajdu MP, Ramírez R, Thulliez P, McLeod R, Remington JS. Role of specific immunoglobulin E in diagnosis of acute Toxoplasma infection and toxoplasmosis. J Clin Microbiol 1993; 31: 2952-9.
69. Yamamoto JH, Vallochi AL, Silveira C, et al. Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens. J Infect Dis 2000; 181: 2018-22.
70. Desmonts G, Baufine-Ducrocq H, Couzineau P, Peloux Y. Natural antibodies against Toxoplasma. Nouv Presse Med 1974; 15: 1547-9.
71. Lappalainen M, Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann 1st Super Sanitá 2004; 40: 81-8.
72. Ferreira AW, Camargo ME. Toxoplasmosis and the laboratory: Diagnosis and a constant striving for improvement. Rev Inst Med Trop S Paulo 2002; 44: 119-20.
73. Jenum PA, Stray-Pedersen B, Gundersen AG. Improved diagnosis of primary Toxoplasma gondii infection in early pregnancy by determination of antitoxoplasma immunoglobulin G avidity. J Clin Microbiol 1997; 35: 1972-7.
74. Hohlfeld P, Daffos F, Costa JM, Thulliez Ph, Forestier F, Vidaud M. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain reaction test on amniotic fluid. N Engl J Med 1994; 331: 685-9.
75. Fricker-Hidalgo H, Pelloux H, Racinet C, et al. Detection of Toxoplasma gondii in 94 placentae from infected women by polymerase chain reaction, in vivo, and in vitro cultures. Placenta 1998; 19: 545-9.
76. Abboud P, Harika G, Saniez D, et al. Signes echographiques de la foetopathie toxoplasmique. J Gynecol Obstet Biol Reprod 1995; 24: 733-8.
77. Gras L, Gilbert RE, Ades AE, Dunn DT. Effect of prenatal treatment on the risk of intracraneal and ocular lesions in children with congenital toxoplasmosis. Int J Epidemiol 2001; 30: 1309-13.
78. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363 (9425): 1965-76.
79. Stray-Pedersen B. Treatment of toxoplasmosis in the pregnant mother and newborn child. Scand J Infect Dis 1992; S84: 23-31.
80. Christoph J, Kattner E, Seitz HN, Reiter-Owona I. Strategien zur Diagnostik und Behandlung der pränatalen Toxoplasma-Infection, ein aktueller Überblick. Z Geburtsh Neonatol 2004; 208: 10-6.
81. Altcheh J, Moscatelli G, Lapeña A, Freilij H. Toxoplasmosis en infecciones perinatales: guía para neonatólogos y pediatras. Prevención, diagnóstico y tratamiento. 1era edición. Buenos Aires: Fundación Sociedad Argentina de Pediatría, 2005, p103-15.
82. Altcheh J, Freilij H. Toxoplasmosis. En: Meneghello J. Tratado de Pediatría. 5ta ed. Buenos Aires: Panamericana, 1997, p1077-80.
83. Patel DV, Holfels EM, Vogel NP, et al. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology 1996; 199: 433-40.
84. Gilbert RE, Gras L, Wallon M, et al. Effect of prenatal treatment in mother to child transmission of Toxoplasma gondii: retrospective cohort study of 554 mother-child pairs in Lyon, France. Int J Epidemiol 2001; 30: 1303-8.
85. McLeod R, Boyer K and The Toxoplasmosis Study Group. Management of and outcome for the newborn infant with congenital toxoplasmosis. In: Ambroise-Thomas P, Petersen E (eds). Congenital Toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 189-213.
86. Ambroise-Thomas P, E Petersen. Congenital toxoplasmosis: past, present and future. In: Ambroise-Thomas P, Petersen E (eds). Toxoplasmose congénitale. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p1-7.
87. Stray-Pedersen B. Prevention of congenital toxoplasmosis in Norway. Arch Pediat 2003; 10: 23-4.
88. Thulliez Ph, Daffos F, Forestier F. Diagnosis of Toxoplasma infection in the pregnant woman and the unborn child: Current problems. Scand J Infect Dis 1992; S84: 18-22.
89. Stray-Pedersen B, Foulon W. Effect of treatment of the infected pregnant woman and her foetus. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000; p141-52.
90. Jenum PA, Stray-Pedersen B, Melby KK, et al. Incidence of Toxoplasma gondii Infection in 35,940 pregnant women in Norway and pregnancy outcome for infected women. J Clin Microbiol 1998; 36: 2900-6.
91. Montoya JG, Rosso F. Diagnosis and management of toxoplasmosis. Clin Perinatol 2005; 32: 705-26.
92. Koppe JG, Lower-Sieger DH, Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986, 1: 254-5.
93. Ambroise-Thomas P. What informations should be extracted from the national programs for the prevention of congenital toxoplasmosis in Austria and in France. In: Ambroise-Thomas P, Petersen E (eds). Congenital toxoplasmosis. Scientific Background, Clinical Management and Control. Chateau-Gontier, France: Springer, 2000, p 299-304.
94. Aspöck H, Pollak A. Prevention of prenatal toxoplasmosis by serological screening of pregnant woman in Austria. Scand J Infect Dis 1992; S84: 32-7.